## Abstract We first classified 12 malignant glioma cell lines into three different groups (types 1–3) with respect to major histocompatibility complex (MHC) class II expression and analyzed each group based on the different expression status of the class II transactivator (CIITA) gene. Glioma type
Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-γ
✍ Scribed by Janet F. Piskurich; Carolyn A. Gilbert; Brittany D. Ashley; Mojun Zhao; Han Chen; Jian Wu; Sophia C. Bolick; Kenneth L. Wright
- Book ID
- 116755626
- Publisher
- Elsevier Science
- Year
- 2006
- Tongue
- English
- Weight
- 358 KB
- Volume
- 43
- Category
- Article
- ISSN
- 0161-5890
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
In order to develop an effective immunotherapy for hematological malignancies, we investigated the applicability of class II transactivator (CIITA), which had been demonstrated to regulate the expression of MHC class II (MHC-II) by assembling the transcription factors of MHC-II molecules, for immuno
## Abstract Malignant gliomas (MGs), lethal human central nervous system (CNS) neoplasms, contain tumor infiltrating lymphocytes (TIL). Although MHC class II molecules are frequently detected on MG cells, suggesting that they may be capable of antigen (Ag) presentation to CD4^+^ T cells, deficienci
## Abstract Downregulation of major histocompatibility complex (MHC) molecules by tumor cells impairs cellular immune recognition and contributes to inefficient cell‐mediated tumor eradication. Low or lack of expression of MHC molecules is frequently observed in early developmental or embryonically